Courtney Wallace is a Venture Partner at Third Rock Ventures, where she focuses on the creation, development, and strategy of new biotechnology companies. Prior to Third Rock, Courtney was an early employee and the Chief Business Officer of Beam Therapeutics. As part of the executive leadership team, she helped lead the company through several important milestones, including advancing programs from discovery stage into the clinic, executing the company’s initial public offering, and implementing partnerships to accelerate the development of precision genetic medicines. Prior to Beam, Courtney was in positions of increasing responsibility at Celgene Corporation, where she was responsible for leading collaborations, licensing transactions, equity investments, and mergers and acquisitions across a variety of therapeutic areas. Earlier in her career, Courtney was a consultant for Easton Associates, where she advised biotechnology and pharmaceutical companies on general corporate strategy, pipeline and portfolio planning, clinical development, sales and marketing activities, and business development. Courtney holds an MBA from Harvard Business School and an AB from Harvard College. Courtney is also an independent board director for Kezar Life Sciences, a clinical stage biotechnology company advancing treatments for patients with autoimmune diseases and cancer.